<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598715</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S02407</org_study_id>
    <nct_id>NCT00598715</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents</brief_title>
  <acronym>DESIRE-2</acronym>
  <official_title>Randomized Trial of Paclitaxel- vs Sirolimus-eluting Stents for Treatment of Coronary Restenosis in Sirolimus-eluting Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For lesions which develop restenosis after a drug-eluting stent, it is not known which the
      right strategy to use is, implantation of the same type of DES as the initial one or a DES
      with a different drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of in-stent restenosis after implantation of a DES has poorly been studied.
      Although there are no data, it may be assumed that certain lesions might be resistant to a
      given drug and in need of a different DES. Thus, for lesions which develop restenosis after a
      DES, it is not known which the right strategy to use is, implantation of the same type of DES
      as the initial one or a DES with a different drug. This prospective, randomized trial will
      compare the anti-restenotic efficacy of PES or SES in patients with restenosis after initial
      implantation of a SES
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late luminal loss at follow-up angiography</measure>
    <time_frame>6-8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need of target lesion revascularization.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined incidence of death or myocardial infarction.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stent thrombosis.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of binary restenosis at follow-up angiography</measure>
    <time_frame>6-8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Same drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sirolimus-eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Different drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paclitaxel eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus eluting stent</intervention_name>
    <description>Sirolimus-eluting stent will be implanted</description>
    <arm_group_label>Same drug</arm_group_label>
    <other_name>Cypher</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel-eluting stent</intervention_name>
    <description>Paclitaxel-eluting stent will be implanted</description>
    <arm_group_label>Different drug</arm_group_label>
    <other_name>Taxus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia
             in the presence of &gt; 50% re- stenosis after prior implantation of Sirolimus eluting
             stents in native coronary vessels

          -  Written, informed consent by the patient or her/his legally-authorized representative
             for participation in the study

          -  In women with childbearing potential a negative pregnancy test is mandatory

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Acute myocardial infarction within the first 48 hours from symptom onset.

          -  Target lesion located in the left main trunk or bypass graft.

          -  Malignancies or other comorbid conditions (for example severe liver, renal and
             pancreatic disease) with life expectancy less than 12 months or that may result in
             protocol non-compliance.

          -  Allergy to antiplatelet therapy, sirolimus, paclitaxel, stainless steel.

          -  Pregnancy (present, suspected or planned) or positive pregnancy test.

          -  Previous enrollment in this trial.

          -  Patient's inability to fully comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julinda Mehilli, MD</last_name>
    <role>Study Director</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1. Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schömig A; ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005 Jan 12;293(2):165-71.</citation>
    <PMID>15644543</PMID>
  </reference>
  <results_reference>
    <citation>Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schömig A, Kastrati A; ISAR-DESIRE 2 Investigators. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol. 2010 Jun 15;55(24):2710-6. doi: 10.1016/j.jacc.2010.02.009. Epub 2010 Mar 11.</citation>
    <PMID>20226618</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2008</study_first_posted>
  <last_update_submitted>December 16, 2010</last_update_submitted>
  <last_update_submitted_qc>December 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Albert Schomig</name_title>
    <organization>Deutsches Herzzentrum Muenchen</organization>
  </responsible_party>
  <keyword>In-stent restenosis</keyword>
  <keyword>In-DES-restenosis</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

